OBJECTIVES: HTAs are frequently required to assess different treatment regimes for different disease types. Frequently, technology appraisal decisions are based on the ICERs estimated from economic models. The aim of this study was to identify any trends in accepted ICER thresholds by disease type. METHODS: All published technology appraisals since April 2005 were downloaded from PBAC, SMC, CADTH, and NICE websites. Appraisals were categorised by disease type according to BNF categories. The manufacturer’s base-case ICERs were extracted and compared across accepted submissions by disease type. RESULTS: Eighteen CADTH, 122 SMC, 81 PBAC and 122 NICE appraisals were identified. For PBAC and SMC, the accepted ICER level (